Previous 10 | Next 10 |
Company to Pursue Low-Grade Serous Ovarian Cancer Indication for VS-6766 with Defactinib; On Track to Initiate Discussions with FDA Company Reports $5.0M in Net Product Revenue; With Newly Strengthened Balance Sheet, Company is Well Positioned to Execute on Key Corporate Objectives in...
Shares of Verastem (NASDAQ: VSTM) -- a small-cap oncology-focused biotech -- were up by 10.9% as of 2:12 p.m. EDT on Monday. The company has not reported any news, though, so the reason behind that stock market rise is a bit of a mystery. However, that gain essentially recouped the stock's F...
Stemline Therapeutics (NASDAQ: STML ) +151% on Menarini bid . More news on: Stemline Therapeutics, Inc., Applied DNA Sciences, Inc., KLX Energy Services Holdings, Inc., Stocks on the move, , Read more ...
The following slide deck was published by Verastem, Inc. in conjunction with this Read more ...
Shares of Verastem Oncology (NASDAQ: VSTM) , a biotechnology company developing novel cancer therapies, are sliding after a highly anticipated data drop failed to impress investors. Shares of the biotech stock were down 42.9% as of 12:12 p.m. EDT on Monday. This year, the American Associatio...
Gainers: Yield10 Bioscience (NASDAQ: YTEN ) +68% . More news on: Yield10 Bioscience, Inc., Aytu BioScience, Inc., Avadel Pharmaceuticals plc, Stocks on the move, , Read more ...
CNX Midstream Partners LP (NYSE: CNXM ) -31% on dividend cut . More news on: CNX Midstream Partners LP, Verastem, Inc., Whiting Petroleum Corporation, Stocks on the move, , Read more ...
Verastem (NASDAQ: VSTM ) announces results from the ongoing investigator-initiated Phase 1 study investigating VS-6766, its RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with KRAS mutant advanced solid tumors. More news on: Verastem, Inc., Healthcare s...
Combination of VS-6766 and Defactinib Demonstrates 67% (4/6 Patients) Overall Response Rate in KRAS Mutant Low-Grade Serous Ovarian Cancer in Phase 1 Trial Subsequent Combined Analysis (VS-6766 Monotherapy and Defactinib Combination) Demonstrates 57% (4/7 Patients) Overall Response Rat...
Normally, companies with share prices lower than $5 -- commonly called penny stocks -- wouldn't even be worth a glance. These types of equities tend to suffer from poor fundamentals, an exorbitant number of outstanding shares, and shaky management. Making matters worse, penny stocks also tend to...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of it...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants t...